Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin
about
Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulumStudy of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virusAntiviral effect of N-butyldeoxynojirimycin against bovine viral diarrhea virus correlates with misfolding of E2 envelope proteins and impairment of their association into E1-E2 heterodimers.Antiviral effects of an iminosugar derivative on flavivirus infectionsImino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agentsNovel Imino Sugar Derivatives Demonstrate Potent Antiviral Activity against FlavivirusesThe heterodimeric structure of glucosidase II is required for its activity, solubility, and localization in vivoMinimal In Vivo Efficacy of Iminosugars in a Lethal Ebola Virus Guinea Pig Modelα-Glucosidase inhibitors as potential broad based anti-viral agentsStrain-specific antiviral activity of iminosugars against human influenza A virusesAnalysis of the pre-S2 N- and O-linked glycans of the M surface protein from human hepatitis B virus.Substrate reduction therapy for glycosphingolipid storage disorders.Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease.The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?Iminosugars: Promising therapeutics for influenza infection.Hepatitis B virus large and middle glycoproteins are degraded by a proteasome pathway in glucosidase-inhibited cells but not in cells with functional glucosidase enzyme.Glucose residues as key determinants in the biosynthesis and quality control of glycoproteins with N-linked oligosaccharides.Modification of the hepatitis B virus envelope protein glycosylation pattern interferes with secretion of viral particles, infectivity, and susceptibility to neutralizing antibodies.Structure-activity relationship of a new class of anti-hepatitis B virus agents.Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein and rescue by a novel glycosylation site.Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo.Evolving therapies for the treatment of chronic hepatitis B virus infection.p53-mediated cellular response to DNA damage in cells with replicative hepatitis B virusIminosugars as possible broad spectrum anti hepatitis virus agents: the glucovirs and alkovirs.Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP).Role of N glycosylation of hepatitis B virus envelope proteins in morphogenesis and infectivity of hepatitis delta virusSelective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocyclesAgents in clinical development for the treatment of chronic hepatitis B.Protease-induced infectivity of hepatitis B virus for a human hepatoblastoma cell line.Iminosugars Inhibit Dengue Virus Production via Inhibition of ER Alpha-Glucosidases--Not Glycolipid Processing Enzymes.Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretionAberrant trafficking of hepatitis B virus glycoproteins in cells in which N-glycan processing is inhibitedHepatitis B surface antigen levels and sequences of natural hepatitis B virus variants influence the assembly and secretion of hepatitis d virus.The alkylated imino sugar, n-(n-Nonyl)-deoxygalactonojirimycin, reduces the amount of hepatitis B virus nucleocapsid in tissue culture.Imino sugar glucosidase inhibitors as broadly active anti-filovirus agentsMetathesis access to monocyclic iminocyclitol-based therapeutic agents.Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors.Role for calnexin and N-linked glycosylation in the assembly and secretion of hepatitis B virus middle envelope protein particles.Molecular mechanisms underlying HBsAg negativity in occult HBV infection.Iminosugar antivirals: the therapeutic sweet spot.
P2860
Q27469618-F3AE81D1-75EA-4DF1-8531-77ECA7EE95ABQ27469853-86835278-10B5-4AAB-841A-90A1CADC3125Q27469899-42546DB6-E2D5-49DF-9AC0-F759CDB0AC0FQ27472863-A349B7CA-2D5D-4F0C-B648-3F13EBF37752Q27478192-FAA39E07-2D7D-4956-ACAF-E938A27A26C5Q27488274-E84CF992-68A3-4A8A-A6C7-4F3310FCA684Q28142779-F62E68E7-19F3-4223-9A7D-955CB7152F6BQ28553683-980DAC9E-5DE2-4563-AF52-D9B686AC3288Q29036682-6783D3CC-A7E9-489C-88AE-D726D146481AQ30366818-0CCC60D6-A84B-4FB1-8A1A-AE03938F164CQ30671216-D2E40037-AB3E-4985-ACD4-097B60D3BF85Q32066333-A9B32B40-CD0C-4C26-BF63-94E0E54AF52FQ33348492-BF849BE6-8130-41E9-8AC6-44F6BFF98A7BQ33717397-91FE5B91-778C-479C-AC1F-8CD1617A7D83Q33795341-BF783912-018D-4005-B5AE-FF9EAE49A884Q34045589-CBECF612-25A5-4D03-AE1F-A0B72EE67E53Q34047041-7478CC69-718F-4FF6-B68A-27313BBF954FQ34059278-4A0F9678-609F-4279-80BF-2CEBDA2AB84DQ34251931-F5B30562-A155-45C4-9121-438E712DF96CQ34416463-BC2AA4F8-FCE8-4846-A672-5F08C25185D0Q34478823-08ECA0AD-B370-45C4-ADA0-70E8FB8E47FAQ34519117-259DAF49-EAE3-433E-BF93-DF321FFE67A0Q34609247-A61B8E2B-66C9-4426-8749-D80434E9B229Q34644755-CB648734-7D45-4D6B-B620-3E5AE1F7BD1CQ34693445-6BB86B1A-3091-4361-9EFE-B45A6DFD9468Q34976217-44C5CE2E-1DEA-4B49-A0E5-050A596DDE6CQ35139139-247C4E2B-BD70-49FA-AC1C-C7BC7C426560Q35185749-9C7E06BA-D5F7-4F6F-8B2D-B92B14B13A05Q35858736-574267C3-F5C0-4789-AA7D-5AAF17BDCEF1Q35956223-0399DB9F-7913-4216-BEA5-5100AD304887Q36023218-952C942D-3471-48AB-B248-E6A08D5E5C86Q36042105-36488EE3-851F-4F58-980C-5BDBCF2BF4D2Q36483922-20EF7EEF-73C0-48E9-8A1D-7126F0AF074BQ36890738-D6D55D2C-1F61-4618-BB88-D45CCFB4829EQ37584342-C7D9A574-0E47-4669-86BC-1ECFBDF8AC39Q37909033-4EDBA8EF-4AA2-4193-894E-C7F4207604DCQ38151881-4CB31975-5512-4E0A-A487-3BC5971A7666Q38341008-691F9541-8DA9-464C-A7CF-6C7C3D8CFEBCQ38536404-C2927D40-D7B9-4D1C-8615-B0FDFD53DE4CQ38730551-B159B474-E91D-40D3-A8FD-F25E2EBE121B
P2860
Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin
description
1994 nî lūn-bûn
@nan
1994 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մարտին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Secretion of human hepatitis B ...... sugar N-butyldeoxynojirimycin
@ast
Secretion of human hepatitis B ...... sugar N-butyldeoxynojirimycin
@en
type
label
Secretion of human hepatitis B ...... sugar N-butyldeoxynojirimycin
@ast
Secretion of human hepatitis B ...... sugar N-butyldeoxynojirimycin
@en
prefLabel
Secretion of human hepatitis B ...... sugar N-butyldeoxynojirimycin
@ast
Secretion of human hepatitis B ...... sugar N-butyldeoxynojirimycin
@en
P2093
P2860
P356
P1476
Secretion of human hepatitis B ...... sugar N-butyldeoxynojirimycin
@en
P2093
Blumberg BS
Gerlich WH
P2860
P304
P356
10.1073/PNAS.91.6.2235
P407
P577
1994-03-01T00:00:00Z